KWM
CYTK icon

Kingsview Wealth Management’s Cytokinetics CYTK Stock Holding History

Kingsview Wealth Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-7,127
Closed -$345K – 852
2022
Q3 		$345K Sell
7,127
-118
-2% -$5.68K 0.02% 599
2022
Q2 		$285K Buy
+7,245
New +$292K 0.01% 677

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Kingsview Wealth Management's CYTK Position: Q4 2022 in Review

Kingsview Wealth Management sold out of Cytokinetics (CYTK) in Q4 2022, closing a stake of 7,127 shares — an estimated $345K sold.

Kingsview Wealth Management first reported a position in CYTK in Q2 2022 and held it in 2 quarters. The position peaked at $345K in Q3 2022. 277 funds tracked by Wall St. Rank hold CYTK as of Q4 2022.

  • Kingsview Wealth Management reported no remaining Cytokinetics position as of Q4 2022 after selling out during the quarter.
  • Kingsview Wealth Management sold 7,127 Cytokinetics shares in Q4 2022, an estimated $345K.
  • Kingsview Wealth Management first reported a position in Cytokinetics in Q2 2022 and held it in 2 quarters.
  • Kingsview Wealth Management's Cytokinetics position peaked at $345K in Q3 2022.
  • 277 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2022.

Based on Kingsview Wealth Management's 13F filing for Q4 2022, filed 13 Feb 2023.